Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease

Area of Science:

• Oncology
• Bone Biology
• Molecular Signaling

Background:

• Multiple myeloma is an incurable malignancy affecting bone marrow.
• Myeloma disrupts bone homeostasis, leading to skeletal damage and pain.
• Current therapies for myeloma bone disease do not restore bone mass.

Purpose of the Study:

• Investigate mechanisms of myeloma-induced bone destruction.
• Identify novel therapeutic targets for myeloma bone disease.
• Explore the role of bone morphogenetic protein (BMP) signaling.

Main Methods:

• Transcriptomic profiling of bone lining cell subtypes in a murine myeloma model.
• Inhibition of BMP signaling in vivo using a small molecule antagonist and a ligand trap.
• Assessment of bone volume, tumor burden, osteoclastogenesis, and osteoblast activity.

Main Results:

• Upregulation of BMP signaling in stromal progenitor cells from myeloma models.
• BMP inhibition prevented trabecular and cortical bone loss without increasing tumor burden.
• BMP inhibition reduced osteoclastogenesis, increased osteoblasts and bone formation, and suppressed sclerostin levels.

Conclusions:

• BMP signaling plays a novel, detrimental role in myeloma-induced bone disease.
• Targeting BMP signaling is a promising therapeutic strategy for myeloma bone disease.
• BMP inhibition promotes anabolic bone activity and suppresses bone resorption in myeloma.